Literature DB >> 19874309

Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.

Marzia Defina, Michela Rondoni, Alessandro Gozzetti, Lara Aprile, Ida Chitarrelli, Alberto Fabbri, Francesco Lauria, Monica Bocchia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19874309     DOI： 10.1111/j.1365-2141.2009.07971.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  3 in total

1.  Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Vu H Duong; Rami S Komrokji; Alan F List
Journal:  Ther Adv Hematol       Date:  2012-04

2.  Long-Term Response in a Patient with del(5q) Myelodysplastic Syndrome Who Discontinued Lenalidomide and Obtained a Good Response and Tolerance to Rechallenge.

Authors:  Francesco Pisani; Giulia Orlandi; Roberta Merola
Journal:  Case Rep Oncol       Date:  2014-04-25

3.  A systematic review of non-standard dosing of oral anticancer therapies.

Authors:  Faouzi Djebbari; Nicola Stoner; Verna Teresa Lavender
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.